Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04248192|
Recruitment Status : Recruiting
First Posted : January 30, 2020
Last Update Posted : March 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|HIV-Infected Individuals||Biological: DD HST-NEETs||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)|
|Actual Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||April 2024|
Experimental: Donor Derived HIV-Specific T-cells (DD HST-NEETs)
Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
Biological: DD HST-NEETs
HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
- Any ≥ Grade 3 Adverse Events (as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0) [ Time Frame: 45 days ]Any ≥ Grade 3 Adverse Events will be measured by number of participants who experience Dose Limiting Toxicity which is attributable to the DD HST-NEETS administration.
- The feasibility of manufacturing of DD HST-NEETs [ Time Frame: 3 years ]Feasibility of the manufacturing process will be measured by generation of the cells in 4 or more donors (i.e., a rate of 50% of more).
- The HIV reservoir measurements [ Time Frame: 3 years ]Summarize the HIV reservoir measurements over the pre-BMT, pre-DD HST-NEETs infusion, post-infusion period to assess any change in the HIV reservoir following infusion.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Participant Inclusion Criteria at Screening:
- Age ≥18 years.
- Confirmation of HIV-1 infection. Any licensed ELISA test kit which is confirmed by Western blot or Multispot HIV-1/HIV-2 assay prior to screening. HIV culture, HIV antigen, plasma HIV RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test.
- On effective antiretroviral therapy.
- Ability and willingness of participant to continue and be compliant with ART throughout the study.
- Hematologic malignancy that qualifies for standard of care alloBMT according to JHU criteria.
- Potential participant must have adequate organ function for standard of care alloBMT according to JHU criteria.
- No active HCV infection. (If seropositive, participant must have no measureable HCV RNA within 30 days of enrollment).
- No active HBV infection (If seropositive, participant must have no measureable HBV DNA or HBsAg+ within 30 days of enrollment).
- Ability and willingness of participant to give written informed consent.
- Ability and willingness to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
- Ability and willingness to provide adequate locator information and contact information for at least 2 adults who can reach the participant within 24 hours
Participant Inclusion Criteria for DD HST-NEETs Infusion:
- Karnofsky score of ≥ 70.
- ANC ≥ 250/µL.
- Bilirubin ≤ 2x upper limit normal or direct bilirubin normal.
- AST ≤ 3x upper limit normal.
- Serum creatinine ≤ 2x upper limit normal.
- Hgb ≥ 7.0 g/dL.
- Pulse oximetry of > 90% on room air.
- Negative pregnancy test in female participants if applicable (childbearing potential).
- Written informed consent signed by participant or guardian.
- Steroids less or equal to 0.5 mg/kg/day prednisone.
Donor Inclusion Criteria for Procurement for DD HST-NEETS Manufacturing:
- Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) hematopoietic cell transplants who have fulfilled eligibility for and consented to stem cell donation as per JHU standard operating procedures.
- Donor must be in good health based on institutional guidelines.
- Female donors of childbearing age must have a negative pregnancy test and must not be lactating.
- It is understood that medical clearance from the donor will be sought within the timeline per the National Marrow Donor Program (NMDP) rules.
- The hematopoietic cell donor will have already been selected by the JHU BMT Donor Selection Committee.
- Donor or parent/guardian capable of providing informed consent
Participant Exclusion Criteria DD HST-NEETs Infusion:
- Participants receiving ATG, or Campath or other immunosuppressive T-cell monoclonal antibodies within 28 days.
- Participants with uncontrolled infections. For bacterial infections, participants must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections participants must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
- Participants who have received donor lymphocyte infusion (DLI) within 28 days.
- Active and uncontrolled relapse of malignancy.
- Participants with active acute GVHD grades II-IV
- Participants with bronchiolitis obliterans syndrome or serositis
- Any licensed or experimental non-HIV vaccination (e.g., hepatitis B, pneumococcal polysaccharide) within 28 days prior to study entry.
- Inability to comply with study requirements, which could impact study integrity and/or safety.
Donor Exclusion Criteria for Procurement for DD HST-NEETs Manufacturing:
• Donor exclusion criteria will be followed as per institution standard operating procedures (SOPs).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04248192
|Contact: Richard Ambinder, MD, PhD||410 firstname.lastname@example.org|
|United States, Maryland|
|Johns Hopkins University(Jhu)||Recruiting|
|Baltimore, Maryland, United States, 21231|
|Contact: Laura Clark, MS PA-C 410-502-5396 email@example.com|
|Principal Investigator: Richard Ambinder, MD, PhD|
|Principal Investigator:||Richard Ambinder, MD, PhD||Johns Hopkins University|
|Principal Investigator:||Michael Keller, MD||CNMC|
|Responsible Party:||Catherine Bollard, Director, Center for Cancer and Immunology Research, Children's National Research Institute|
|Other Study ID Numbers:||
|First Posted:||January 30, 2020 Key Record Dates|
|Last Update Posted:||March 4, 2022|
|Last Verified:||March 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|